Compare Adaptive Biotechnologies Corp (ADPT) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Payoneer Global Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.57 (market cap $4.04B), while Payoneer Global Inc trades at $7.1 (market cap $2.40B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap. Which is the better fit depends on your goals.
| ADPT | PAYO | |
|---|---|---|
Market Cap | $4.04B | $2.40B |
Sector | Health | Technology |
52-Week High | $25.45 | $7.17 |
52-Week Low | $12.30 | $4.27 |
Enterprise Value | $4.10B | $2.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Payoneer Global Inc. (PAYO) trades at $7.09, down 0.14% on the day, near its 52-week high of $7.67. The stock shows a bullish technical signal with strong moving averages, while fundamentals reveal mixed earnings with Q2 2026 EPS missing estimates at $0.02 versus $0.06 expected. Revenue growth remains solid, up 10% year-over-year excluding interest in Q2 2026. Sentiment is influenced by the pending acquisition by Nuvei for $7.40 per share, announced on June 15, 2026, which has sparked legal inquiries over fairness.
The outlook is cautiously optimistic with a consensus price target of $8.20 offering 16% upside, but risks include integration challenges from the Nuvei deal and earnings volatility. Investors should weigh the acquisition premium against potential shareholder litigation and execution risks in cross-border payment growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
